Trials / Completed
CompletedNCT02770261
Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy
A Multi-center, Randomized, Double-blind, Parellel Phase III Clinical Trial to Evaluate the Efficacy and Safety of DP-R208 and Each Monotherapy in Patients With Hypertension and Primary Hypercholesterolemia.
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 219 (actual)
- Sponsor
- Alvogen Korea · Industry
- Sex
- All
- Age
- 19 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determine superiority of DP-R208 compare to each monotherapy in patient with hypertension and primary hypercholesterolemia.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | DP-R208 | DP-R208 + Candesartan 32mg placebo + Rosuvastatin 20mg placebo |
| DRUG | Candesartan32mg | DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo |
| DRUG | Rosuvastatin 20mg | DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg |
| DRUG | DP-R208 Placebo | DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg |
| DRUG | Candesartan32mg Placebo | DP-R208 placebo + Candesartan 32mg placebo + Rosuvastatin 20mg |
| DRUG | Rosuvastatin 20mg Placebo | DP-R208 placebo + Candesartan 32mg + Rosuvastatin 20mg placebo |
Timeline
- Start date
- 2015-12-01
- Primary completion
- 2016-08-01
- Completion
- 2016-10-01
- First posted
- 2016-05-12
- Last updated
- 2016-12-26
Locations
1 site across 1 country: South Korea
Source: ClinicalTrials.gov record NCT02770261. Inclusion in this directory is not an endorsement.